Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

15.7%

27 terminated/withdrawn out of 172 trials

Success Rate

80.3%

-6.3% vs industry average

Late-Stage Pipeline

33%

56 trials in Phase 3/4

Results Transparency

69%

76 of 110 completed trials have results

Key Signals

17 recruiting76 with results21 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2

57(34.8%)

Phase 3

47(28.7%)

Phase 1

46(28.0%)

Phase 4

9(5.5%)

Early Phase 1

3(1.8%)

N/A

2(1.2%)

164Total

Phase 2(57)

Phase 3(47)

Phase 1(46)

Phase 4(9)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (172)

Showing 20 of 172 trials

NCT03644667Phase 2Completed

Tocilizumab in Cardiac Transplantation

Role: collaborator

NCT07247266Phase 1Completed

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Role: collaborator

NCT06343298Phase 2Recruiting

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Role: collaborator

NCT03949855Phase 2Recruiting

Belimumab With Rituximab for Primary Membranous Nephropathy

Role: collaborator

NCT05671757Phase 1Recruiting

Daratumumab in Primary Antiphospholipid Syndrome

Role: collaborator

NCT04047628Phase 3Recruiting

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Role: collaborator

NCT06594068Phase 4Recruiting

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Role: collaborator

NCT07015996Phase 2Recruiting

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Role: collaborator

NCT06795893Recruiting

The Anifrolumab PRIM Program

Role: collaborator

NCT04392739Phase 4Completed

Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG

Role: collaborator

NCT04485039Phase 4Completed

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Role: collaborator

NCT06659029Recruiting

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Role: collaborator

NCT07053800Phase 2Recruiting

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Role: collaborator

NCT04133909Phase 3Completed

Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Role: collaborator

NCT06703073Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Role: lead

NCT06701682Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Role: lead

NCT06701669Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Role: lead

NCT06701656Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

Role: lead

NCT06134362Phase 3Active Not Recruiting

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Role: collaborator

NCT04827979Phase 1Completed

Daratumumab and Belatacept for Desensitization

Role: collaborator